Interius生物治疗学开始第一阶段试验INT2104,一种针对B细胞恶性肿瘤的基因疗法。 Interius BioTherapeutics initiates Phase 1 trial of INT2104, a gene therapy targeting B-cell malignancies.
Interius生物治疗学已经启动了INVISE第一阶段临床试验,向第一位病人注射了INT2104,这是针对B细胞恶性肿瘤的新型基因疗法。 Interius BioTherapeutics has initiated the INVISE Phase 1 clinical trial by dosing its first patient with INT2104, a novel gene therapy targeting B-cell malignancies. 这种一流治疗在病人身体内产生CAR-T和CAR-NK细胞,作为单剂量静脉注射进行,消除了专门程序的必要性。 This first-in-class treatment generates CAR-T and CAR-NK cells within the patient's body and is administered as a single-dose intravenous infusion, eliminating the need for specialized procedures. 初步安全和功效数据将于2025年提交。 Preliminary safety and efficacy data will be presented in 2025.